Zobrazeno 1 - 2
of 2
pro vyhledávání: '"MJ Neri Crespo"'
PS-021 Natalizumab discontinuation in patients diagnosed with relapsing remitting multiple sclerosis
Autor:
MT Sánchez Sánchez, A.M. López González, MN Téllez Lara, MJ Neri Crespo, J Varela González-Aller, ME Cárdaba García
Publikováno v:
Patient safety and risk management.
Background Natalizumab is effective in relapsing remitting multiple sclerosis (RRMS) treatment, although it is associated with serious adverse events that may require therapy discontinuation. Purpose To assess the reasons for discontinuing natalizuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eea254a4d6d6690ca98ae337780957e2
https://doi.org/10.1136/ejhpharm-2017-000640.527
https://doi.org/10.1136/ejhpharm-2017-000640.527
Autor:
Mulero P; Neurology Department, University Clinical Hospital of Valladolid, Castilla y León, Spain. pamuca84@hotmail.com, Caminero AB, Neri Crespo MJ, Fernández-Herranz R, Téllez Lara N
Publikováno v:
Journal of neuroimmunology [J Neuroimmunol] 2012 Feb 29; Vol. 243 (1-2), pp. 103-5. Date of Electronic Publication: 2012 Jan 05.